



## CONTENTS

<b>Chapter 1</b>	General introduction and outline of the thesis	9
<b>Chapter 2</b>	Chronic myeloid leukemia in the Netherlands: a population-based study on incidence, treatment and survival in 3,585 patients from 1989-2012	25
<b>Chapter 3</b>	The EUTOS population-based registry: incidence and clinical characteristics of 2,904 CML patients in twenty European countries	43
<b>Chapter 4</b>	High-dose imatinib versus high-dose imatinib in combination with intermediate-dose cytarabine in patients with first chronic phase myeloid leukemia: a randomized phase III trial of the Dutch-Belgian HOVON study group	63
<b>Chapter 5</b>	Imatinib discontinuation in chronic phase myeloid leukaemia patients in sustained complete molecular response: a randomised trial of the Dutch-Belgian Cooperative Trial Group for Haemato-Oncology (HOVON)	79
<b>Chapter 6</b>	New insights in the pathogenesis of chronic myeloid leukemia: towards a path to cure	93
<b>Chapter 7</b>	Leukemic stem cell quantification in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP) predicts response to nilotinib: results from the ENEST1st stem cell substudy	119
<b>Chapter 8</b>	Summary and future perspectives	139
<b>Appendices</b>	Samenvatting voor medisch niet-ingewijden	145
	Curriculum Vitae	157
	List of Publications	161
	Dankwoord	167